CN1923199A - Use of chloride 13-hexyl berberine and chloride 13-hexyl palmatine in preparation of medicine for treating moist tetter, dermatitis and psoriasis - Google Patents
Use of chloride 13-hexyl berberine and chloride 13-hexyl palmatine in preparation of medicine for treating moist tetter, dermatitis and psoriasis Download PDFInfo
- Publication number
- CN1923199A CN1923199A CN 200510094085 CN200510094085A CN1923199A CN 1923199 A CN1923199 A CN 1923199A CN 200510094085 CN200510094085 CN 200510094085 CN 200510094085 A CN200510094085 A CN 200510094085A CN 1923199 A CN1923199 A CN 1923199A
- Authority
- CN
- China
- Prior art keywords
- hexyl
- chloride
- medicine
- psoriasis
- dermatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention relates to a method for using alcaine 13-hexyl berberine, and relative lcaine 13-palmatine to prepare external the drug that resists dermopathy and psoriasis. And it has antibacterial activity and better treatment on eczema, etc. And its emulsion can treat psoriasis with similar effect of Simvastatin, without side effect.
Description
Technical field
The invention relates to the purposes of inflammatory skin medicines such as chemical compound chloride 13-hexyl berberine (calling HB-13 in the following text) ex hoc genus anne thing HP-13 (calling HP-13 in the following text) preparation external preparation for skin antieczematic, dermatitis.
Background technology
HB-13 molecular formula C
26H
31NO
4HCl, molecular weight 457.98 has following chemical structural formula:
Above-mentioned HB-13 is by hexyl-C by the 13rd-H in parent compound berberine hydrochloride (the calling Bo in the following text) molecule
6H
13The derivant that replaces and get, adopt berberine hydrochloride in aqueous medium with the sodium borohydride sig water react dihydroberberine, reuse n-hexyl aldehyde and dihydroberberine react in ethanol acetate liquid and generate the crude product chloride 13-hexyl berberine, and be further refining then and get.
As everyone knows, Bo is isolated a kind of monomer in the Rhizoma Coptidis total alkaloids that extracts from plants such as Rhizoma Coptidis, Bo has the activity of anti-dysentery bacillus and certain anti-Bacillus typhi, streptococcus pneumoniae, golden staphylococci, has been widely used in treating diseases such as gastroenteritis, bacillary dysentery, typhoid fever.Also there is its oral administration of report that more weak Chinese People's Anti-Japanese Military and Political College's Mus inflammatory model effect is arranged, but do not see the practicality report.
The still untapped at present medicine that becomes of the derivant HB-13 of Bo does not also see that it has the anti-immunity of treatment eczema, dermatitis and psoriasis aspect, antiinflammatory, antiproliferative and antibacterial activity report.
HP-13 molecular formula C
27H
35NO
4HCl, molecular weight 474.02 has following chemical structural formula:
HP-13 is by hexyl-C by the 13rd-H in parent compound hydrochloric acid fibrauretin (the being called for short Po) molecule
6H
13The derivant that replaces and get, the hydrochloric acid fibrauretin is former to be a kind of antimicrobial drug.But HP-13 does not see about it to have the activity of treatment eczema, dermatitis and psoriasis aspect and the report of purposes.Experimental results show that HP-13 and HB-13 have quite similar character aspect pharmacologically active and the purposes.
Summary of the invention
The purpose of this invention is to provide HB-13 and the HP-13 application in preparation treatment eczema, dermatitis and psoriasis medicine.
The present invention has done and clinical relevant experimentation compound H B-13, finds that it is having unprecedented activity and purposes aspect treatment eczema, dermatitis and the psoriasis.
Eczema and dermatitis are to be comprised the delayed allergy disease that physics, chemistry, biological inducements such as environment, weather, food, medicine, article of everyday use, disease, metabolism, infection, spiritual nerve-endocrine, heredity are brought out by multiple internal and external factor.Also can occur together in its morbidity and the progression antibacterial, fungus or other pathogenic infection, the latter needs suitably add with whole body or local anti-infective therapy simultaneously.At present topical therapeutic mainly adopts the compound preparation of 17-hydroxy-11-dehydrocorticosterone or itself and medicine compositions such as antibacterium, antifungal, antiviral.
Psoriasis is the cell-mediated dysimmunity disease of T, local skin infringement with inflammatory infiltration, hyperproliferative epidermal and disdifferentiation, and the corium blood capillary to generate pathological changes such as unusual serve as main performance, numerous cytokine and the inflammatory mediator abnormal expressions of companion system and part.Psoriatic Drug therapy comprises system and topical, though topical therapeutic can only obtain the temporary alleviation of skin lesion, but its untoward reaction is less, especially psoriasis still can not effect a radical cure so far, medicine there is lifelong dependence, so one of measure that topical therapeutic is independent or the association system administration is indispensable.
The present invention is by relevant measuring, anti-immunity, antiinflammatory, the antiproliferative of compound H B-13 treatment eczema, dermatitis and psoriatic principle and the antibacterial activity that infects that often occurs together have been done research, comprising the test of pesticide effectiveness with whole animal, cell and molecular level, comprise anti-all kinds of microbiological tests, to the cytokine of skin epithelial cell, lymphocyte, inflammatory cell and expression thereof and the influence and subsequent the preliminary clinical trial of inflammatory mediator.External agar plate method bacteriostatic test confirms: HB-13 and HP-13 significantly strengthen than its former generation compd B o the antibacterial activity of skin advantage suppuration bacterium, to staphylococcus aureus, staphylococcus epidermidis, escherichia coli and bacillus pyocyaneus MIC value is 3.125 μ g/ml, stronger 80～320 times respectively than Bo (staphylococcus aureus MIC value is 250 μ g/ml, and escherichia coli MIC value is＞1000 μ g/ml); Anti-dermatophytosis and Candida albicans MIC value are respectively 25～50 and 50～100 μ g/ml, and be stronger 10～20 times than Bo (Candida albicans MIC value is 500 μ g/ml).In addition zoopery is found, 0.5～1%HB-13 or HP-13 gel or emulsifiable paste can anti-Oleum Tiglii cause mice ear and ultraviolet causes the guinea pig skin erythema.HB-13 has the very strong anti-proinflammatory cytokine and the effect of inflammatory mediator, and 5 μ g～20 μ g/ml concentration ranges can suppress rat abdominal cavity macrophage, rat splenocyte and human peripheral blood single nucleus cell proinflammatory cytokine and inflammatory mediator activity such as excretory IL-1, IL-8, IFN-γ and TNF-α under relevant derivant effect.Cell in vitro is cultivated and the antiproliferative test shows, HB-13 forms the IC of cell HaCaT cell strain and epithelial cancer cells to normal skin keratin
50Value is 15～25g/ml, and it suppresses T lymphopoiesis concentration is＜1 μ g/ml.These all are the not available activity of Bo.Above-mentioned antibiotic, antiinflammatory, anti-immunocompetence are the treatment a variety of causes allergic eczema of bringing out, dermatitis (simple or companion infect) and psoriatic pharmacological basis.Above-mentioned these discoveries show pharmacology of this derivant and the therapeutics characteristic has played amount and matter compared with its former generation compd B o variation.
The present invention through above same test, prove that itself and compound H B-13 have similar pharmacological action, and its former generation Compound P o finds no these effects to compound H P-13.
It is ointment and gel that HB-13 of this indication or HP-13 are suitable for preparation, show through clinical preliminary examination: the gel of HB-13 or HP-13 content 0.5～1.0% or emulsifiable paste are effective to acute, the subacute and chronic eczema dermatitis class dermatosis that a variety of causes brings out, and the effect 17-hydroxy-11-dehydrocorticosterone is close in its effect and the external; In addition, because HB-13 has anti-skin common bacteria and fungus effect, to all types of eczemas, dermatitis occur together or the infected by microbes of secondary also effective, so imitate the therapeutic effect of the compound preparation of 17-hydroxy-11-dehydrocorticosterone and antibacterials composition in substituting, thereby can avoid because of abusing the adverse consequences that 17-hydroxy-11-dehydrocorticosterone produces.On the other hand, with concentration is that the ointment external psoriatic lesion of 1% HB-13 or HP-13 is effective, reaction and make erythema soak into attenuation can diminish inflammation, effective to psoriasis inflammation and activeness proliferative skin lesion, effect and middle effect 17-hydroxy-11-dehydrocorticosterone and chemical antipsoriatic tazarotene are close, but can not cause the untoward reaction as 17-hydroxy-11-dehydrocorticosterone, its list is used and formed compound recipe should have original effect aspect the treatment psoriasis.The percent unit that this paper relates to is g/ml.
The specific embodiment
The preparation of embodiment one gel
Take by weighing:
Compound H B-13 or HP-13 0.2～2g
Surfactant 0.5～1g
Dehydrated alcohol 5～20ml
Third ethanol, 10～20g
Carpopol
940 0.5～2g
Triethanolamine is an amount of
Distilled water adds to 100g
Above prescription is mixed with the external-use gel agent medicine by the gel conventional method.
The preparation of embodiment two ointments
Take by weighing:
Compound H B-13 or HP-13 0.5～2g glycerol 5～10g
Hexadecanol 6～8g dehydrated alcohol is an amount of
White vaseline 8～10g ethyl ester 0.1g
White oil 8～19g monoglyceride 2～5g
Polyoxyethylene (40) stearate 2～5g distilled water adds to 100g
More than prescription is made o/w ointment medicine by the ointment routine operation.
Using method: be applied to eczema, dermatitis class skin infection affected part in right amount with above gel, ointment.
Claims (8)
1. the application of chloride 13-hexyl berberine in preparation treatment eczema, dermatitis disease external used medicine.
2. the application in HP-13 preparation treatment eczema, the dermatitis disease external used medicine.
3. the application of chloride 13-hexyl berberine in preparation treatment psoriasis medicine.
4. the application in the sick psoriasis medicine of HP-13 preparation treatment.
5. according to the application of claim 1, it is characterized in that described medicine is gel or ointment.
6. according to the application of claim 2, it is characterized in that described medicine is gel or ointment.
7. according to the medicinal usage of claim 3, it is characterized in that described medicine is an ointment.
8. according to the medicinal usage of claim 4, it is characterized in that described medicine is an ointment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100940855A CN100441183C (en) | 2005-08-29 | 2005-08-29 | Use of chloride 13-hexyl berberine and chloride 13-hexyl palmatine in preparation of medicine for treating moist tetter, dermatitis and psoriasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100940855A CN100441183C (en) | 2005-08-29 | 2005-08-29 | Use of chloride 13-hexyl berberine and chloride 13-hexyl palmatine in preparation of medicine for treating moist tetter, dermatitis and psoriasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1923199A true CN1923199A (en) | 2007-03-07 |
| CN100441183C CN100441183C (en) | 2008-12-10 |
Family
ID=37816142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100940855A Expired - Fee Related CN100441183C (en) | 2005-08-29 | 2005-08-29 | Use of chloride 13-hexyl berberine and chloride 13-hexyl palmatine in preparation of medicine for treating moist tetter, dermatitis and psoriasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100441183C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101104618B (en) * | 2007-05-25 | 2010-05-26 | 西南大学 | Long chain alkyl berberine salt derivative, synthetic method and use |
| WO2011000218A1 (en) * | 2009-06-30 | 2011-01-06 | Shuen-Lu Huang | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
| JP2020505362A (en) * | 2017-01-19 | 2020-02-20 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | Methods and pharmaceutical compositions for preventing or treating immunoinflammatory skin disorders |
| EP3777856A4 (en) * | 2018-04-13 | 2021-06-09 | Institute Of Materia Medica, Chinese Academy Of Medical Sciences | Hydrophilic berberine-type derivative and application thereof in preparing drug |
| WO2024045809A1 (en) * | 2022-08-30 | 2024-03-07 | 南京纽邦生物科技有限公司 | Method and composition for improving health of hair follicles, scalp or hair of mammals |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE55519B1 (en) * | 1982-05-14 | 1990-10-10 | Maroko Peter R | Use of a protoberberine alkaloid and composition containing same |
| JPH0395116A (en) * | 1989-09-07 | 1991-04-19 | Takeda Chem Ind Ltd | Reverse transcriptase-inhibiting composition |
| WO1998000018A1 (en) * | 1996-07-03 | 1998-01-08 | Prm Pharmaceuticals, Inc. | Berberine alkaloids as a treatment for chronic, protozoally-induced diarrhea |
| KR100258849B1 (en) * | 1998-04-24 | 2000-08-01 | 박원배 | Pharmaceutically useful protoberberine derivative and its salts |
-
2005
- 2005-08-29 CN CNB2005100940855A patent/CN100441183C/en not_active Expired - Fee Related
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101104618B (en) * | 2007-05-25 | 2010-05-26 | 西南大学 | Long chain alkyl berberine salt derivative, synthetic method and use |
| WO2011000218A1 (en) * | 2009-06-30 | 2011-01-06 | Shuen-Lu Huang | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
| CN102481290A (en) * | 2009-06-30 | 2012-05-30 | 德安生医有限公司 | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
| RU2533458C2 (en) * | 2009-06-30 | 2014-11-20 | Дерман Байомедисин Ко. Лтд. | Compositions containing berberine or its analogues for treating skin diseases related to rosacea or blush |
| AU2010268647B2 (en) * | 2009-06-30 | 2015-01-15 | Derman Biomedicine Co. Ltd. | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
| US9486402B2 (en) | 2009-06-30 | 2016-11-08 | Derman Biomedicine Co. Ltd | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
| RU2671492C2 (en) * | 2009-06-30 | 2018-11-01 | Дерман Байомедисин Ко. Лтд. | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
| JP2020505362A (en) * | 2017-01-19 | 2020-02-20 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | Methods and pharmaceutical compositions for preventing or treating immunoinflammatory skin disorders |
| EP3777856A4 (en) * | 2018-04-13 | 2021-06-09 | Institute Of Materia Medica, Chinese Academy Of Medical Sciences | Hydrophilic berberine-type derivative and application thereof in preparing drug |
| US11725006B2 (en) | 2018-04-13 | 2023-08-15 | Institute Of Materia Medic, Chinese Academy Of Medical Sciences | Hydrophilic berberine-type derivative and application thereof in preparing drug |
| WO2024045809A1 (en) * | 2022-08-30 | 2024-03-07 | 南京纽邦生物科技有限公司 | Method and composition for improving health of hair follicles, scalp or hair of mammals |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100441183C (en) | 2008-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Murphy et al. | β-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects—Implications for coronavirus disease (COVID-19) immunotherapies | |
| JP6239041B2 (en) | Tamarind seed polysaccharide for use in the treatment of microbial infections | |
| CN100441183C (en) | Use of chloride 13-hexyl berberine and chloride 13-hexyl palmatine in preparation of medicine for treating moist tetter, dermatitis and psoriasis | |
| KR100700912B1 (en) | Human Cell Binding Inhibitory Activity of Acne Bacillus and Atopic Staphylococcus aureus Containing Acidic Polysaccharides Isolated from Green Tea Leaves | |
| Mukherjee et al. | Ameliorative effects of Artemisia pallens in a murine model of ovalbumin-induced allergic asthma via modulation of biochemical perturbations | |
| Hua et al. | Study on the antiinflammatory activity of methanol extract from seagrass Zostera japonica | |
| KR20150008086A (en) | Compositions for topical treatment of microbial infections | |
| JP2022516983A (en) | Rhodococcus louver products and their pharmaceutical use | |
| Tipton et al. | Methamphetamine cytotoxicity and effect on LPS-stimulated IL-1β production by human monocytes | |
| Pereira et al. | Immunomodulatory effect of Canova medication on experimental Leishmania amazonensis infection | |
| Mahattanadul et al. | Oral ulcer healing and anti-Candida efficacy of an alcohol-free chitosan-curcumin mouthwash | |
| CN1879661B (en) | Use of nocardia rubra cell wall skeleton in preparation of medicine for resisting mycotic infection | |
| Wang et al. | Enhanced efficacy of chemically modified curcumin in experimental periodontitis: systemic implications | |
| Rahmani et al. | Effect of 0.5% Chitosan mouthwash on recurrent aphthous stomatitis: A randomized double-blind crossover clinical trial | |
| Zu et al. | Effective fraction of Bletilla striata reduces the inflammatory cytokine production induced by water and organic extracts of airborne fine particulate matter (PM 2.5) in vitro | |
| KR100791420B1 (en) | Acidic polysaccharide extracted from mugwort and its composition for the use of preventing human cellular interaction of Propionibacterium acnes and Staphylococcus aureus | |
| Hwang et al. | Modulation of experimental atopic dermatitis by topical application of Gami-Cheongyeul-Sodok-Eum | |
| Cheng et al. | Isoorientin Alleviates Inflammatory Bowel Disease by Inhibiting NLRP3 Inflammasome Activation through Nrf2/NQO1 Pathway. | |
| Liu et al. | Scorpio and Scolopendra attenuate inflammation and articular damage in rats with collagen-induced arthritis | |
| Lima et al. | Anti-inflammatory activity and acute toxicity studies of hydroalcoholic extract of Herissantia tiubae | |
| Buzia¹ et al. | Antibacterial action of certain tretinoin and benzoyl peroxide liposomes. Case study | |
| CN101224245A (en) | Quality controlling method of Chinese traditional medicine for treating gynecology inflammation | |
| CN113975228A (en) | Gynecological antibacterial gel and application thereof | |
| Sirisha et al. | Antimicrobial effect of silver nanoparticles synthesised with Ocimum sanctum leaf extract on periodontal pathogens | |
| Jeong et al. | β-Glucan-enriched fermented barley bran (Sigumjang meju) extracts attenuates gastric mucosal injury induced by acute alcohol intake in vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081210 Termination date: 20210829 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |